All In Biotech

Drug Trial Radar · NCT04906083

Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia

The Efficacy and Safety of Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia: A Multicenter, Prospective, Randomized Controlled Trial(EAST)

Last checked: Nov 20, 2026Latest source record: Jun 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

150

Planned (sponsor's estimate)

Start

Feb 1, 2021

Primary completion

Dec 31, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Tongji HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Anhui Provincial Hospital; The First Affiliated Hospital of Nanchang University; Taihe Hospital, Hubei University of Medicine; The First Hospital of Jilin University
First posted
May 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

End stage liver disease is prone to thrombocytopenia. This study is a multi-center, randomized, prospective, randomized controlled Phase IV Clinical trial to discuss the Efficacy and Safety of Avatrombopag in Patients with End-stage Liver Disease and Thrombocytopenia.

Conditions

  • Liver Failure
  • Thrombocytopenia
  • Decompensated Cirrhosis

Interventions

  • AvatrombopagDrug

    Avatrombopag: PLT:30\~50×10\^9/L patients, 40 mg/d; PLT:\<30×10\^9/L patients, 60 mg/d.

  • Standard medical treatmentDrug

    Standard medical treatment included transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Platelet count response timeTime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of infectious disease, Tongji Hospital

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.